Metropolitan Life Insurance Company (MetLife)’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2022
Q1
Sell
-21,304
Closed -$1.81M 2527
2021
Q4
$1.81M Sell
21,304
-365
-2% -$31.1K 0.02% 593
2021
Q3
$2.08M Sell
21,669
-718
-3% -$68.9K 0.03% 482
2021
Q2
$2.18M Sell
22,387
-240
-1% -$23.4K 0.03% 485
2021
Q1
$2.2M Buy
22,627
+15,640
+224% +$1.52M 0.03% 479
2020
Q4
$670K Sell
6,987
-136
-2% -$13K 0.01% 1172
2020
Q3
$685K Sell
7,123
-185
-3% -$17.8K 0.01% 984
2020
Q2
$892K Buy
7,308
+902
+14% +$110K 0.02% 804
2020
Q1
$554K Sell
6,406
-130
-2% -$11.3K 0.01% 993
2019
Q4
$703K Sell
6,536
-122
-2% -$13.1K 0.01% 1123
2019
Q3
$600K Buy
6,658
+24
+0.4% +$2.16K 0.01% 1184
2019
Q2
$560K Sell
6,634
-153
-2% -$12.9K 0.01% 1237
2019
Q1
$598K Sell
6,787
-72
-1% -$6.34K 0.01% 1179
2018
Q4
$490K Sell
6,859
-22
-0.3% -$1.57K 0.01% 1203
2018
Q3
$846K Sell
6,881
-137
-2% -$16.8K 0.01% 1024
2018
Q2
$689K Buy
7,018
+400
+6% +$39.3K 0.01% 1108
2018
Q1
$549K Buy
6,618
+91
+1% +$7.55K 0.01% 1214
2017
Q4
$506K Sell
6,527
-61
-0.9% -$4.73K 0.01% 1282
2017
Q3
$404K Buy
6,588
+336
+5% +$20.6K ﹤0.01% 1826
2017
Q2
$288K Buy
6,252
+351
+6% +$16.2K ﹤0.01% 2104
2017
Q1
$256K Hold
5,901
﹤0.01% 2106
2016
Q4
$228K Sell
5,901
-267
-4% -$10.3K ﹤0.01% 2271
2016
Q3
$312K Sell
6,168
-296
-5% -$15K ﹤0.01% 2038
2016
Q2
$294K Sell
6,464
-53,312
-89% -$2.42M ﹤0.01% 2061
2016
Q1
$2.36M Buy
59,776
+320
+0.5% +$12.7K 0.02% 844
2015
Q4
$3.36M Buy
59,456
+581
+1% +$32.9K 0.03% 675
2015
Q3
$2.34M Buy
58,875
+191
+0.3% +$7.6K 0.02% 850
2015
Q2
$2.8M Buy
+58,684
New +$2.8M 0.02% 818
2015
Q1
Sell
-57,136
Closed -$1.28M 2362
2014
Q4
$1.28M Sell
57,136
-3,864
-6% -$86.3K 0.01% 1183
2014
Q3
$956K Hold
61,000
0.01% 1301
2014
Q2
$905K Buy
61,000
+3,236
+6% +$48K 0.01% 1423
2014
Q1
$930K Buy
57,764
+1,501
+3% +$24.2K 0.01% 1392
2013
Q4
$525K Hold
56,263
﹤0.01% 1786
2013
Q3
$637K Hold
56,263
﹤0.01% 1587
2013
Q2
$753K Buy
+56,263
New +$753K 0.01% 1419